Teleflex Incorporated (NYSE:TFX) CEO Benson Smith sold 2,000 shares of Teleflex stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $258.10, for a total value of $516,200.00. Following the sale, the chief executive officer now directly owns 76,634 shares of the company’s stock, valued at approximately $19,779,235.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Teleflex Incorporated (NYSE:TFX) traded down $1.23 during mid-day trading on Tuesday, reaching $251.75. The company had a trading volume of 341,516 shares, compared to its average volume of 260,808. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. The stock has a market capitalization of $11,450.00, a PE ratio of 32.83, a P/E/G ratio of 2.27 and a beta of 1.09. Teleflex Incorporated has a 52 week low of $151.22 and a 52 week high of $271.23.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. The company had revenue of $534.70 million during the quarter, compared to analysts’ expectations of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. Teleflex’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the business earned $1.80 earnings per share. research analysts anticipate that Teleflex Incorporated will post 8.35 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Wednesday, November 15th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date is Tuesday, November 14th. Teleflex’s dividend payout ratio (DPR) is presently 24.55%.

A number of equities research analysts recently commented on TFX shares. Jefferies Group lifted their target price on Teleflex from $253.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, September 8th. Needham & Company LLC lifted their target price on Teleflex from $228.00 to $237.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $232.00 price target for the company in a research report on Friday, September 1st. Deutsche Bank reiterated a “buy” rating and set a $238.00 price target (up from $220.00) on shares of Teleflex in a research report on Wednesday, August 9th. Finally, Stephens reiterated a “buy” rating and set a $270.00 price target (up from $230.00) on shares of Teleflex in a research report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $274.44.

Several institutional investors have recently bought and sold shares of TFX. Toronto Dominion Bank increased its position in shares of Teleflex by 14.5% in the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after buying an additional 70 shares in the last quarter. Advisory Services Network LLC increased its position in shares of Teleflex by 933.8% in the second quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after buying an additional 747 shares in the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new stake in shares of Teleflex in the second quarter valued at approximately $175,000. Calamos Advisors LLC purchased a new stake in shares of Teleflex in the second quarter valued at approximately $206,000. Finally, Advisor Partners LLC purchased a new stake in shares of Teleflex in the second quarter valued at approximately $212,000. Institutional investors and hedge funds own 89.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Teleflex Incorporated (TFX) CEO Sells 2,000 Shares of Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/insider-selling-teleflex-incorporated-tfx-ceo-sells-2000-shares-of-stock.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.